Recommended Topic Related To:

Selzentry

"Nov. 27, 2012 -- Every month, 1,000 more young Americans ages 13 to 24 get an incurable infection that's deadly unless held at bay by daily doses of costly drugs -- and many of them don't even know it.

That infection is HIV, the virus"...

Selzentry

Selzentry Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Selzentry (maraviroc) is an antiviral medication used together with other medications to treat CCR5-tropic human immunodeficiency virus (HIV) type 1. It is not a cure for HIV or AIDS. Common side effects include cough, stomach pain, tiredness, and lightheadedness or dizziness while standing.

The recommended dose of Selzentry differs based on other medications taken at the same time due to drug interactions. Selzentry must be given in combination with other antiretroviral medications. Selzentry may interact with conivaptan, imatinib, isoniazid, nefazodone, rifampin, St. John's wort, seizure medications, antibiotics, antifungals, heart or blood pressure medications, or HIV/AIDS medicines. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant before using Selzentry. It is unknown if this medication passes into breast milk. Because breast milk can transmit HIV, do not breastfeed.

Our Selzentry (maraviroc) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Selzentry in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Maraviroc may also cause severe liver symptoms. Stop taking maraviroc and call your doctor at once if you have any of these liver symptoms:

  • low fever, itching;
  • nausea, upper stomach pain, loss of appetite;
  • dark urine, clay-colored stools; or
  • jaundice (yellowing of the skin or eyes).

Call your doctor at once if you have any other serious side effect, such as:

  • skin rash, bruising, severe tingling, numbness, pain, muscle weakness;
  • sudden numbness, tingling, or weakness anywhere in your body;
  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
  • cold sores, sores on your genital or anal area;
  • white patches or sores inside your mouth or on your lips; or
  • signs of a new infection, such as fever or chills, cough, or flu symptoms.

Less serious side effects may include:

  • cold symptoms such as stuffy nose, sneezing, cough, sore throat;
  • diarrhea, constipation;
  • sleep problems (insomnia);
  • swelling;
  • problems with urination;
  • muscle or joint pain;
  • dizziness; or
  • mild skin rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Selzentry (Maraviroc) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Selzentry Overview - Patient Information: Side Effects

SIDE EFFECTS: See also Warning section.

Cough, stomach pain, or tiredness may occur. Lightheadedness or dizziness while standing may also occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Some people may experience worsening of a previous medical condition (such as an old infection) as their immune systems improve, or develop new conditions because their immune systems have become overactive. This reaction may occur at any time (soon after starting HIV treatment or many months later). Tell your doctor right away if you have any serious side effects, including: unexplained weight loss, persistent muscle aches/weakness, joint pain, numbness/tingling of the hands/feet/arms/legs, severe tiredness, vision changes, severe/persistent headaches, signs of infection (such as fever, chills, trouble breathing, cough, non-healing skin sores), signs of an overactive thyroid (such as irritability, nervousness, heat intolerance, fast/pounding/irregular heartbeat, bulging eyes, unusual growth in the neck/thyroid known as a goiter), signs of a certain nerve problem known as Guillain-Barre Syndrome (such as difficulty breathing/swallowing/moving your eyes, drooping face, paralysis, slurred speech).

Seek immediate medical attention if any of these rare but very serious side effects occur: chest/jaw/left arm pain.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any of the following symptoms: rash, rash with fever, skin peeling/blisters, mouth sores, redness/swelling of the eyes, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Selzentry (Maraviroc)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Selzentry FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The following adverse reactions are discussed in other sections of the labeling:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Trials in Treatment-Experienced Subjects

The safety profile of SELZENTRY is primarily based on 840 HIV-1-infected subjects who received at least 1 dose of SELZENTRY during two Phase 3 trials. A total of 426 of these subjects received the indicated twice-daily dosing regimen.

Assessment of treatment-emergent adverse events is based on the pooled data from 2 trials in subjects with CCR5-tropic HIV-1 (A4001027 and A4001028). The median duration of therapy with SELZENTRY for subjects in these trials was 48 weeks, with the total exposure on SELZENTRY twice daily at 309 patient-years versus 111 patient-years on placebo + optimized background therapy (OBT). The population was 89% male and 84% white, with mean age of 46 years (range: 17 to 75 years). Subjects received dose equivalents of 300 mg maraviroc once or twice daily.

The most common adverse events reported with twice-daily therapy with SELZENTRY with frequency rates higher than placebo, regardless of causality, were upper respiratory tract infections, cough, pyrexia, rash, and dizziness. Additional adverse events that occurred with once-daily dosing at a higher rate than both placebo and twice-daily dosing were diarrhea, edema, influenza, esophageal candidiasis, sleep disorders, rhinitis, parasomnias, and urinary abnormalities. In these 2 trials, the rate of discontinuation due to adverse events was 5% for subjects who received SELZENTRY twice daily + OBT as well as those who received placebo + OBT. Most of the adverse events reported were judged to be mild to moderate in severity. The data described below occurred with twice-daily dosing of SELZENTRY.

The total number of subjects reporting infections were 233 (55%) and 84 (40%) in the group receiving SELZENTRY twice daily and the placebo group, respectively. Correcting for the longer duration of exposure on SELZENTRY compared with placebo, the exposure-adjusted frequency (rate per 100 subject-years) of these events was 133 for both SELZENTRY twice daily and placebo.

Dizziness or postural dizziness occurred in 8% of subjects on either SELZENTRY or placebo, with 2 subjects (0.5%) on SELZENTRY permanently discontinuing therapy (1 due to syncope, 1 due to orthostatic hypotension) versus 1 subject on placebo (0.5%) permanently discontinuing therapy due to dizziness.

Treatment-emergent adverse events, regardless of causality, from A4001027 and A4001028 are summarized in Table 3. Selected events occurring at ≥ 2% of subjects and at a numerically higher rate in subjects treated with SELZENTRY are included; events that occurred at the same or higher rate on placebo are not displayed.

Table 3: Percentage of Subjects With Selected Treatment-Emergent Adverse Events (All Causality) ≥ 2% on SELZENTRY (and at a higher rate compared with placebo) Trials A4001027 and A4001028 (Pooled Analysis, 48 Weeks) NR = Not recommended.

Body System/ Adverse Event SELZENTRY Twice Dailya Placebo
N = 426 (%) Exposure-adjusted rate (per 100 ptyrs)
PYE = 309b
N = 209 (%) Exposure-adjusted rate (per 100 ptyrs)
PYE = 111b
Eye Disorders
  Conjunctivitis 2 3 1 3
  Ocular infections, inflammations, and associated manifestations 2 3 1 2
Gastrointestinal Disorders
  Constipation 6 9 3 6
General Disorders and Administration Site Conditions
  Pyrexia 13 20 9 17
  Pain and discomfort 4 5 3 5
Infections and Infestations
  Upper respiratory tract infection 23 37 13 27
  Herpes infection 8 11 4 8
  Sinusitis 7 10 3 6
  Bronchitis 7 9 5 9
  Folliculitis 4 5 2 4
  Pneumonia 2 3 5 10
  Anogenital warts 2 3 1 3
  Influenza 2 3 0.5 1
  Otitis media 2 3 0.5 1
Metabolism and Nutrition Disorders
  Appetite disorders 8 11 7 13
Musculoskeletal and Connective Tissue Disorders
  Joint-related signs and symptoms 7 10 3 5
  Muscle pains 3 4 0.5 1
Neoplasms Benign, Malignant, and Unspecified
  Skin neoplasms benign 3 4 1 3
Nervous System Disorders
  Dizziness/postural dizziness 9 13 8 17
  Paresthesias and dysesthesias 5 7 3 6
  Sensory abnormalities 4 6 1 3
  Disturbances in consciousness 4 5 3 6
  Peripheral neuropathies 4 5 3 6
Psychiatric Disorders
  Disturbances in initiating and maintaining sleep 8 11 5 10
  Depressive disorders 4 6 3 5
  Anxiety symptoms 4 5 3 7
Renal and Urinary Disorders
  Bladder and urethral symptoms 5 7 1 3
  Urinary tract signs and symptoms 3 4 1 3
Respiratory, Thoracic, and Mediastinal Disorders
  Coughing and associated symptoms 14 21 5 10
  Upper respiratory tract signs and symptoms 6 9 3 6
  Nasal congestion and inflammations 4 6 3 5
  Breathing abnormalities 4 5 2 5
  Paranasal sinus disorders 3 4 0.5 1
Skin and Subcutaneous Tissue Disorders
  Rash 11 16 5 11
  Apocrine and eccrine gland disorders 5 7 4 7.5
  Pruritus 4 5 2 4
  Lipodystrophies 3 5 0.5 1
  Erythemas 2 3 1 2
Vascular Disorders
  Vascular hypertensive disorders 3 4 2 4
a300-mg dose equivalent.
bPYE = Patient-years of exposure.

Laboratory Abnormalities

Table 4 shows the treatment-emergent Grade 3-4 laboratory abnormalities that occurred in > 2% of subjects receiving SELZENTRY.

Table 4: Maximum Shift in Laboratory Test Values (Without Regard to Baseline) Incidence ≥ 2% of Grade 3-4 Abnormalities (ACTG Criteria) Trials A4001027 and A4001028 (Pooled Analysis, 48 Weeks)

Laboratory Parameter Preferred Term Limit SELZENTRY Twice Daily + OBT
(N = 421)a %
Placebo + OBT
(N = 207)a %
Aspartate aminotransferase > 5.0 x ULN 4.8 2.9
Alanine aminotransferase > 5.0 x ULN 2.6 3.4
Total bilirubin > 2.5 x ULN 5.5 5.3
Amylase > 2.0 x ULN 5.7 5.8
Lipase > 2.0 x ULN 4.9 6.3
Absolute neutrophil count < 750/mm³ 4.3 2.4
aPercentages based on total subjects evaluated for each laboratory parameter.
ULN=upper limit of normal.

Trial in Treatment-Naive Subjects

Treatment-Emergent Adverse Events: Treatment-emergent adverse events, regardless of causality, from Trial A4001026, a double-blind, comparative, controlled trial in which 721 treatment-naive subjects received SELZENTRY 300 mg twice daily (N = 360) or efavirenz (N = 361) in combination with zidovudine/lamivudine for 96 weeks, are summarized in Table 5. Selected events occurring in ≥ 2% of subjects and at a numerically higher rate in subjects treated with SELZENTRY are included; events that occurred at the same or higher rate on efavirenz are not displayed.

Table 5: Percentage of Subjects With Selected Treatment-Emergent Adverse Events (All Causality) ( ≥ 2% on SELZENTRY and at a higher rate compared with efavirenz) Trial A4001026 (96 Weeks)

Body System/ Adverse Event SELZENTRY 300 mg Twice Daily + Zidovudine/ Lamivudine
(N = 360)
%
Efavirenz 600 mg Once Daily + Zidovudine/ Lamivudine
(N = 361)
%
Blood and Lymphatic System Disorders
  Anemias NEC 8 5
  Neutropenias 4 3
Ear and Labyrinth Disorders
  Ear disorders NEC 3 2
Gastrointestinal Disorders
  Flatulence, bloating, and distention 10 7
  Gastrointestinal atonic and hypomotility disorders NEC 9 5
  Gastrointestinal signs and symptoms NEC 3 2
General Disorders and Administration Site Conditions
  Body temperature perception 3 1
Infections and Infestations
  Bronchitis 13 9
  Herpes infection 7 6
  Upper respiratory tract infection 32 30
  Bacterial infections NEC 6 3
  Herpes zoster/varicella 5 4
  Lower respiratory tract and lung infections 3 2
  Neisseria infections 3 0
  Tinea infections 4 3
  Viral infections NEC 3 2
Musculoskeletal and Connective Tissue Disorders
  Joint-related signs and symptoms 6 5
Nervous System Disorders
  Memory loss (excluding dementia) Paresthesias and dysesthesias 3 4 1 3
Renal and Urinary Disorders
  Bladder and urethral symptoms 4 3
Reproductive System and Breast Disorders
  Erection and ejaculation conditions and disorders 3 2
Respiratory, Thoracic, and Mediastinal Disorders
  Upper respiratory tract signs and symptoms 9 5
Skin and Subcutaneous Disorders
  Acnes 3 2
  Alopecias 2 1
  Lipodystrophies 4 3
  Nail and nail bed conditions (excluding infections and infestations) 6 2

Laboratory Abnormalities

Table 6: Maximum Shift in Laboratory Test Values (Without Regard to Baseline) Incidence ≥ 2% of Grade 3-4 Abnormalities (ACTG Criteria) Trial A4001026 (96 Weeks)

Laboratory Parameter
Preferred Term
Limit SELZENTRY 300 mg Twice Daily + Zidovudine/ Lamivudine
(N = 353)a %
Efavirenz 600 mg Once Daily+ Zidovudine/ Lamivudine
(N = 350)a %
Aspartate aminotransferase > 5.0 x ULN 4 4
Alanine aminotransferase > 5.0 x ULN 3.9 4
Creatine kinase 3.9 4.8
Amylase > 2.0 x ULN 4.3 6
Absolute neutrophil count < 750/mm³ 5.7 4.9
Hemoglobin < 7.0 g/dL 2.9 2.3
aN = Total number of subjects evaluable for laboratory abnormalities.
ULN=upper limit of normal.

Percentages based on total subjects evaluated for each laboratory parameter. If the same subject in a given treatment group had > 1 occurrence of the same abnormality, only the most severe is counted.

Less Common Adverse Events in Clinical Trials

The following adverse events occurred in < 2% of subjects treated with SELZENTRY. These events have been included because of their seriousness and either increased frequency on SELZENTRY or are potential risks due to the mechanism of action. Events attributed to the patient's underlying HIV-1 infection are not listed.

Blood and Lymphatic System: Marrow depression and hypoplastic anemia.

Cardiac Disorders: Unstable angina, acute cardiac failure, coronary artery disease, coronary artery occlusion, myocardial infarction, myocardial ischemia.

Hepatobiliary Disorders: Hepatic cirrhosis, hepatic failure, cholestatic jaundice, portal vein thrombosis, hypertransaminasemia, jaundice.

Infections and Infestations: Endocarditis, infective myositis, viral meningitis, pneumonia, treponema infections, septic shock, Clostridium difficile colitis, meningitis.

Musculoskeletal and Connective Tissue Disorders: Myositis, osteonecrosis, rhabdomyolysis, blood CK increased.

Neoplasms Benign, Malignant, and Unspecified (Including Cysts and Polyps): Abdominal neoplasm, anal cancer, basal cell carcinoma, Bowen's disease, cholangiocarcinoma, diffuse large B-cell lymphoma, lymphoma, metastases to liver, esophageal carcinoma, nasopharyngeal carcinoma, squamous cell carcinoma, squamous cell carcinoma of skin, tongue neoplasm (malignant stage unspecified), anaplastic large cell lymphomas T-and null-cell types, bile duct neoplasms malignant, endocrine neoplasms malignant and unspecified.

Nervous System Disorders: Cerebrovascular accident, convulsions and epilepsy, tremor (excluding congenital), facial palsy, hemianopia, loss of consciousness, visual field defect.

Postmarketing Experience

The following events have been identified during post-approval use of SELZENTRY and are not listed above. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to estimate their frequency or establish a causal relationship to exposure to SELZENTRY.

Skin and Subcutaneous Tissue Disorders

Stevens-Johnson syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis (TEN).

Read the entire FDA prescribing information for Selzentry (Maraviroc) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.